Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SELECTA BIOSCIENCES, INC.

(SELB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SELECTA BIOSCIENCES INC : Other Events (form 8-K)

09/08/2021 | 08:07am EDT
Item 8.01 Other Events.
On September 7, 2021, Selecta Biosciences, Inc. (the "Company") entered into a
Collaboration and License Agreement (the "Agreement") with Cyrus Biotechnology,
Inc. ("Cyrus"). Under the Agreement, Cyrus agreed to grant the Company an
exclusive, worldwide license to certain intellectual property in order to form a
protein engineering collaboration combining the Company's ImmTOR platform with
Cyrus' ability to redesign protein therapeutics. The lead program in the
collaboration is a proprietary interleukin-2 (IL-2) protein agonist designed to
selectively promote expansion of regulatory T cells for the treatment of
patients with autoimmune diseases and other deleterious immune conditions. The
Company expects that novel engineered protein therapeutic candidates from the
partnership will be used to expand the Company's proprietary pipeline and
further bolster its ImmTOR platform.
In return for the licensed intellectual property, Selecta is obligated to make
an upfront payment and pay certain discovery, development, and sales-based
milestones which could potentially total up to approximately $1.5 billion across
multiple programs.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about SELECTA BIOSCIENCES, INC.
10/13SELECTA BIOSCIENCES : to Present New Data for the ImmTOR™ platform at the ESGCT 28th..
AQ
10/04SELECTA BIOSCIENCES : Signs Deal with Takeda Worth Up to $1.12 Billion for Next-Generation..
MT
10/04SELECTA BIOSCIENCES : Working With Takeda Pharmaceutical to Develop Gene Therapies for Lys..
MT
10/04SELECTA BIOSCIENCES INC : Other Events (form 8-K)
AQ
10/04Selecta Biosciences Announces Strategic Licensing Agreement with Takeda to Develop Next..
GL
10/04Selecta Biosciences Announces Strategic Licensing Agreement with Takeda to Develop Next..
CI
09/30SELECTA BIOSCIENCES INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,..
AQ
09/30Selecta Biosciences, Inc. Files Investigational New Drug Application with the U.S. Food..
CI
09/21Selecta Biosciences to Participate in Cantor Virtual Global Healthcare Conference
GL
09/20SELECTA BIOSCIENCES : Names Kevin Tan Finance Chief
MT
More news
Analyst Recommendations on SELECTA BIOSCIENCES, INC.
More recommendations